

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **TATA Health International Holdings Limited**

### **TATA 健康國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1255)**

- (1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE OF COMPOSITION OF BOARD COMMITTEES;**
  - (2) RESIGNATION OF NON-EXECUTIVE DIRECTOR;**
  - (3) RESIGNATION OF CHIEF FINANCIAL OFFICER; AND**
  - (4) NON-COMPLIANCE WITH RULE 3.10(2) OF THE LISTING RULES**
- (1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE OF COMPOSITION OF BOARD COMMITTEES**

The board (“**Board**”) of directors (“**Director(s)**”) of TATA Health International Holdings Limited (the “**Company**”) hereby announces that Mr. WANG Jian (王儉) (“**Mr. Wang**”) has tendered his resignation as an independent non-executive Director and ceased to be the chairman of each of the audit committee (the “**Audit Committee**”), the remuneration committee (the “**Remuneration Committee**”) and the nomination committee (the “**Nomination Committee**”) of the Company, with effect from 3 September 2025, due to his decision to devote more time to his other work arrangements.

Mr. Wang has confirmed that he does not have any disagreement with the Board and that there is no other matter relating to his resignation which needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to extend its gratitude to Mr. Wang for his past valuable contributions to the Company during his tenure of office.

Following the resignation of Mr. Wang, Ms. HUANG Lin (黃琳) (“**Ms. Huang**”), an independent non-executive Director, has been appointed as the chairman of each of the Audit Committee, the Remuneration Committee and the Nomination Committee in place of Mr. Wang, with effect from 3 September 2025. Biographical details of Ms. Huang are set out in the announcement of the Company dated 8 July 2025.

## **(2) RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The Board further announces that Mr. LIN Zheming (林哲明) (“**Mr. Lin**”) has tendered his resignation as a non-executive Director, with effect from 3 September 2025, due to his decision to devote more time to his other work arrangements.

Mr. Lin has confirmed that he does not have any disagreement with the Board and that there is no other matter relating to his resignation which needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to extend its gratitude to Mr. Lin for his past valuable contributions to the Company during his tenure of office.

## **(3) RESIGNATION OF CHIEF FINANCIAL OFFICER**

The Board further announces that Mr. LAI Wenjing (賴文敬) (“**Mr. Lai**”) has tendered his resignation as the chief financial officer of the Company (the “**Chief Financial Officer**”), with effect from 3 September 2025, due to his decision to devote more time to his other work engagements.

Mr. Lai has confirmed that he does not have any disagreement with the Board and that there is no other matter relating to his resignation which needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to extend its gratitude to Mr. Lai for his past valuable contributions to the Company during his tenure of office.

## **(4) NON-COMPLIANCE WITH RULE 3.10(2) OF THE LISTING RULES**

Pursuant to Rule 3.10(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on the Stock Exchange, at least one of the independent non-executive Directors must have appropriate professional qualifications or accounting or related financial management expertise. Following the resignation of Mr. Wang, none of the existing independent non-executive Directors possess appropriate professional qualifications or accounting or related financial management expertise as prescribed under Rule 3.10(2) of the Listing Rules.

As at the date of this announcement, the Company is in the process of identifying a suitable candidate so as to fulfill the requirements under Rule 3.10(2) of the Listing Rules, and will endeavour to appoint such candidate as independent non-executive Director as soon as practicable within three months from 3 September 2025. The Company will make further announcement in relation to such appointment as and when appropriate in accordance with the Listing Rules.

By Order of the Board  
**TATA Health International Holdings Limited**  
**Zhang Ming Qi**  
*Non-executive Director*

Hong Kong, 3 September 2025

*As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Chu Chun Ho, Dominic, Mr. Zhang Ming Qi and Mr. Chen Qi; and three independent non-executive Directors, namely, Ms. Huang Lin, Mr. Li Liang and Mr. Du Jianfeng.*